The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Towards Better Definition, Quantification and Treatment of Fibrosis in Heart Failure. A Scientific Roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology
Open accessAbstract
Fibrosis is a pivotal player in heart failure development and progression. Measurements of (markers of) fibrosis in tissue and blood may help to diagnose and risk stratify patients with heart failure, and its treatment may be effective in preventing heart failure and its progression. A lack of pathophysiological insights and uniform definitions has hampered the research in fibrosis and heart failure. The Translational Research Committee of the Heart Failure Association discussed several aspects of fibrosis in their workshop. Early insidious perturbations such as subclinical hypertension or inflammation may trigger first fibrotic events, while more dramatic triggers such as myocardial infarction and myocarditis give rise to full blown scar formation and ongoing fibrosis in diseased hearts. Aging itself is also associated with a cardiac phenotype that includes fibrosis. Fibrosis is an extremely heterogeneous phenomenon, as several stages of the fibrotic process exist, each with different fibrosis subtypes and a different composition of various cells and proteins — resulting in a very complex pathophysiology. As a result, detection of fibrosis, e.g. using current cardiac imaging modalities or plasma biomarkers, will detect only specific subforms of fibrosis, but cannot capture all aspects of the complex fibrotic process. Furthermore, several anti-fibrotic therapies are under investigation, but such therapies generally target aspecific aspects of the fibrotic process and suffer from a lack of precision. This review discusses the mechanisms and the caveats and proposes a roadmap for future research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541
MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts
Thum, T., Gross, C., Fiedler, J., Fischer, T., Kissler, S., Bussen, M., Galuppo, P., Just, S., Rottbauer, W., Frantz, S., et al. (2008) · Nature · doi:10.1038/nature07511 · Cited by 2,349
Self-citationThe myofibroblast in wound healing and fibrocontractive diseases
Gabbiani, G. (2003) · The Journal of Pathology · doi:10.1002/path.1427 · Cited by 1,630
The pathogenesis of cardiac fibrosis
Kong, P., Christia, P., & Frangogiannis, N. G. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1349-6 · Cited by 1,567
Gulati, A., Jabbour, A., Ismail, T. F., Guha, K., Khwaja, J., Raza, S., Morarji, K., Brown, T. D. H., Ismail, N. A., Dweck, M. R., et al. (2013) · JAMA · doi:10.1001/jama.2013.1363 · Cited by 1,179
Self-citationPhenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap
Shah, S. J., Kitzman, D. W., Borlaug, B. A., van Heerebeek, L., Zile, M. R., Kass, D. A., & Paulus, W. J. (2016) · Circulation · doi:10.1161/circulationaha.116.021884 · Cited by 1,003
Sharma, U. C., Pokharel, S., van Brakel, T. J., van Berlo, J. H., Cleutjens, J. P. M., Schroen, B., André, S., Crijns, H. J. G. M., Gabius, H. J., Maessen, J., et al. (2004) · Circulation · doi:10.1161/01.cir.0000147181.65298.4d · Cited by 947
Bozkurt, B., Kribbs, S. B., Clubb, F. J., Michael, L. H., Didenko, V. V., Hornsby, P. J., Seta, Y., Oral, H., Spinale, F. G., & Mann, D. L. (1998) · Circulation · doi:10.1161/01.cir.97.14.1382 · Cited by 821
Iles, L., Pfluger, H., Phrommintikul, A., Cherayath, J., Aksit, P., Gupta, S. N., Kaye, D. M., & Taylor, A. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.06.049 · Cited by 736
Cited by
Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches
López, B., Ravassa, S., Moreno, M. U., José, G. S., Beaumont, J., González, A., & Díez, J. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00504-1 · Cited by 361
Therapeutic Potential of Centella asiatica and Its Triterpenes: A Review
Sun, B., Wu, L., Wu, Y., Zhang, C., Qin, L., Hayashi, M., Kudo, M., Gao, M., & Liu, T. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.568032 · Cited by 353
Withaar, C., Meems, L. M. G., Markousis-Mavrogenis, G., Boogerd, C. J., Silljé, H. H. W., Schouten, E. M., Dokter, M. M., Voors, A. A., Westenbrink, B. D., Lam, C. S. P., et al. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa256 · Cited by 223
Delivery of modified mRNA to damaged myocardium by systemic administration of lipid nanoparticles
Evers, M. J. W., Du, W., Yang, Q., Kooijmans, S. A. A., Vink, A., van Steenbergen, M., Vader, P., de Jager, S. C. A., Fuchs, S. A., Mastrobattista, E., et al. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.027 · Cited by 113
Self-citationMittelheisser, V., Gensbittel, V., Bonati, L., Li, W., Tang, L., & Goetz, J. G. (2024) · Nature Nanotechnology · doi:10.1038/s41565-023-01535-8 · Cited by 109
Metadata
- Authors
- de Boer, R. A., De Keulenaer, G., Bauersachs, J., Brutsaert, D., Cleland, J. G., Diez, J., Du, X.-J., Ford, P., Heinzel, F. R., Lipson, K. E., McDonagh, T., Lopez-Andres, N., Lunde, I. G., Lyon, A. R., Pollesello, P., Prasad, S. K., Tocchetti, C. G., Mayr, M., Sluijter, J. P. G., Thum, T., Tschöpe, C., Zannad, F., Zimmermann, W.-H., Ruschitzka, F., Filippatos, G., Lindsey, M. L., Maack, C., & Heymans, S.
- Venue
- European Journal of Heart Failure
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-02-04
- Volume
- 21
- Issue
- 3
- Pages
- 272-285
- ISSN
- 1388-9842 (ISSN-L)
- 1879-0844
- OpenAlex
- W2912308947
- Cited by
- 304
- References
- 91
- FWCI
- 24.78
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Towards Better Definition, Quantification and Treatment of Fibrosis in Heart Failure. A Scientific Roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. https://app.cochat.ai/papers/10.1002/ejhf.1406
- The paper
- de Boer, R. A., De Keulenaer, G., Bauersachs, J., Brutsaert, D., Cleland, J. G., Diez, J., Du, X.-J., Ford, P., Heinzel, F. R., Lipson, K. E., McDonagh, T., Lopez-Andres, N., Lunde, I. G., Lyon, A. R., Pollesello, P., Prasad, S. K., Tocchetti, C. G., Mayr, M., Sluijter, J. P. G., . . . Heymans, S. (2019). Towards Better Definition, Quantification and Treatment of Fibrosis in Heart Failure. A Scientific Roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.1406
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
